238 related articles for article (PubMed ID: 25506917)
1. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.
Tozbikian G; Brogi E; Kadota K; Catalano J; Akram M; Patil S; Ho AY; Reis-Filho JS; Weigelt B; Norton L; Adusumilli PS; Wen HY
PLoS One; 2014; 9(12):e114900. PubMed ID: 25506917
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin expression and survival outcomes in triple receptor negative breast cancer.
Parinyanitikul N; Blumenschein GR; Wu Y; Lei X; Chavez-Macgregor M; Smart M; Gonzalez-Angulo AM
Clin Breast Cancer; 2013 Oct; 13(5):378-84. PubMed ID: 23810431
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
5. Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review.
Wang M; Li A; Sun G; Mbuagbaw L; Reid S; Lovrics PJ; Thabane L
Syst Rev; 2016 Aug; 5(1):133. PubMed ID: 27514374
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
7. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
Del Bano J; Florès-Florès R; Josselin E; Goubard A; Ganier L; Castellano R; Chames P; Baty D; Kerfelec B
Front Immunol; 2019; 10():1593. PubMed ID: 31354732
[TBL] [Abstract][Full Text] [Related]
8. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
9. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
10. Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer.
Wang CA; Liu Q; Chen Y; Liu S; Xu J; Cui X; Zhang Y; Piao L
Exp Mol Pathol; 2015 Apr; 98(2):254-9. PubMed ID: 25617527
[TBL] [Abstract][Full Text] [Related]
11. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
13. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin expression is associated with poor outcomes in breast cancer.
Li YR; Xian RR; Ziober A; Conejo-Garcia J; Perales-Puchalt A; June CH; Zhang PJ; Tchou J
Breast Cancer Res Treat; 2014 Oct; 147(3):675-84. PubMed ID: 25193277
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases.
Gangi A; Mirocha J; Leong T; Giuliano AE
Ann Surg Oncol; 2014 Dec; 21(13):4098-103. PubMed ID: 25155393
[TBL] [Abstract][Full Text] [Related]
16. Primary relapse site pattern in women with triple-negative breast cancer.
Beca F; Santos R; Vieira D; Zeferino L; Dufloth R; Schmitt F
Pathol Res Pract; 2014 Sep; 210(9):571-5. PubMed ID: 24939141
[TBL] [Abstract][Full Text] [Related]
17. Platinum-based chemotherapy in triple-negative advanced breast cancer.
Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S
Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of prognostic factors related to triple-negative breast cancer].
Shen SJ; Sun Q; Zhou YD; Guan JH; Mao F; Lin Y; Peng L; Xu Y; Wang XF; Xia W; Yao R; Han SM
Zhonghua Wai Ke Za Zhi; 2013 Nov; 51(11):1000-4. PubMed ID: 24444685
[TBL] [Abstract][Full Text] [Related]
20. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
